Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology

Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
Conditions: Muscle-Invasive Bladder Carcinoma; Tumor

Interventions: Drug: Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)

Sponsors: Leslie Ballas

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 18, 2024Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments